Staar Surgical CO Form 4 insider transactions

Broadwood Partners, L.P., along with related entities and individuals, increased its holdings in STAAR Surgical Co. through a series of open market purchases between April 8 and April 10, 2025.

Broadwood Partners, a significant shareholder in STAAR Surgical Co, has increased its holdings through a series of open market purchases between April 3rd and April 7th, 2025.

Broadwood Partners, L.P., along with related entities and individuals, reports acquiring additional shares of STAAR Surgical Co. common stock, increasing their beneficial ownership.

Broadwood Partners, a significant shareholder in STAAR Surgical Co, has increased its holdings through a series of open market purchases, as indicated in a Form 4 filing.

Broadwood Partners, L.P. reports increased ownership in STAAR Surgical Co. through recent stock purchases.

Broadwood Partners, along with related entities and individuals, has increased its holdings in STAAR Surgical Co through a series of open market purchases.

Warren Foust, President and COO of STAAR Surgical, was granted restricted stock units (RSUs) on March 14, 2025, as part of an annual equity award and in connection with his promotion.

Magda Michna, Chief Development Officer of STAAR Surgical, received restricted stock units (RSUs) as part of an annual equity award and in connection with her promotion.

Nathaniel Sisitsky, Chief Legal Officer of STAAR Surgical Co., reports the acquisition of restricted stock units (RSUs) related to annual equity awards and a promotion.

Warren Foust, COO of STAAR Surgical, reports the vesting and disposal of restricted stock units.

Magda Michna, Chief Clinical, Regulatory, and Medical Affairs Officer of STAAR Surgical, reports the vesting and disposal of restricted stock units to cover tax obligations.

Nathaniel Sisitsky, General Counsel of STAAR Surgical, reports exercising stock options and disposing of shares to cover tax obligations on March 12, 2025.

Patrick F. Williams, CFO of STAAR Surgical, reports the vesting of restricted stock units on March 12, 2025.

Patrick F. Williams, CFO of STAAR Surgical, reports the vesting of performance stock units and restricted stock units.

Broadwood Partners, along with related entities and individuals, reports acquiring additional shares of STAAR Surgical Co common stock, increasing their beneficial ownership.

Stephen C. Farrell, President and CEO of STAAR Surgical, exercised stock options on March 5, 2025, acquiring 20,000 shares of common stock.

Broadwood Partners, along with related entities and individuals, reported the acquisition of additional shares of STAAR Surgical Co common stock between February 27, 2025, and March 3, 2025, increasing their holdings.

Stephen Farrell, the newly appointed President and CEO of STAAR Surgical, was granted 200,000 restricted stock units (RSUs) as a sign-on equity award.

Broadwood Partners, L.P., along with related entities and individuals, has increased its holdings in STAAR Surgical Co (STAA) through a series of open market purchases.

Broadwood Partners, L.P. has increased its holdings in STAAR Surgical Co. through a series of open market purchases.

Staar Surgical CEO Thomas Frinzi sold 10,775 shares of common stock to cover taxes related to a vesting restricted stock unit award.

Broadwood Partners, L.P. has increased its holdings in STAAR Surgical Co. through a series of open market purchases.

Director Arthur C. Butcher of STAAR Surgical Co. reports the acquisition and disposal of common stock on August 12, 2024.

Director Stephen Farrell acquired shares and options in STAAR Surgical Co. on June 20, 2024, as part of the company's non-employee director equity compensation program.

Director Zhou Lilian Yansheng reported acquiring shares of STAAR Surgical Co. through restricted stock and options grants, while also disposing of shares.

Director Aimee S. Weisner reports acquisition of 4,488 shares of STAAR Surgical Co. common stock through a restricted stock grant.

Director Arthur Butcher reports acquiring and disposing of STAAR Surgical shares, including restricted stock and options, as part of the company's non-employee director equity compensation program.

Director Wei Jiang reports acquisition of 2,244 shares and disposal of 3,543 shares of STAAR Surgical Co. common stock, along with the acquisition of 4,010 common stock options.

Director Elizabeth Yeu reported the acquisition of common stock and options in STAAR Surgical Co. on June 20, 2024, as part of the company's annual non-employee director equity compensation program.

Broadwood Partners, L.P. reports the acquisition of STAAR Surgical Co stock, increasing its holdings to 10,768,431 shares.